Biopharm Distribution SPA

Biopharm Distribution SPA is a prominent pharmaceutical importer and distributor based in Algeria, specializing in the procurement and distribution of finished pharmaceutical formulations. The company operates as a Société par Actions (SPA), a form of joint-stock company, and is headquartered in Zone Industrielle Oued Smar, Lot N°62, Voie n°36, 16270 Oued Smar, Algeria. Under the leadership of CEO Mr. Abdelmadjid Kerrar, Biopharm Distribution SPA plays a pivotal role in Algeria's pharmaceutical supply chain, ensuring the availability of essential medications to meet the country's healthcare needs.

The company's extensive import portfolio includes a diverse range of pharmaceutical products, encompassing various therapeutic categories such as respiratory, cardiovascular, and gastrointestinal treatments. This broad spectrum underscores Biopharm Distribution SPA's commitment to addressing a wide array of medical conditions prevalent in Algeria. By maintaining a robust distribution network, the company ensures that these critical medications are accessible to healthcare providers and patients across the nation.

Biopharm Distribution SPA's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout Algeria. The company's primary warehouse is located in Zone Industrielle Oued Smar, 16270 Oued Smar, Algeria. This central location facilitates streamlined logistics and timely distribution to various regions within the country. While specific details regarding additional warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established infrastructure capable of supporting nationwide distribution.

Biopharm Distribution SPA serves as a key player in Algeria's pharmaceutical supply chain, primarily functioning as a pharmaceutical importer and distributor. The company's role involves sourcing finished pharmaceutical formulations from international suppliers, including Indian manufacturers, and ensuring their availability to healthcare providers and patients across Algeria. By maintaining a diverse product portfolio and a robust distribution network, Biopharm Distribution SPA contributes significantly to the accessibility and reliability of pharmaceutical products in the Algerian market.

Biopharm Distribution SPA's sourcing strategy exhibits a high degree of concentration, with a significant reliance on a limited number of suppliers. The company's total import value from India amounts to $5.6 million USD, encompassing 112 shipments and 91 unique formulations. Notably, two Indian suppliers dominate this sourcing landscape:

• CIPLA LIMITED: Accounting for $6.4 million USD across 245 shipments, representing 99.8% of the total import value.

• J B CHEMICALS AND PHARMACEUTICALS LIMITED: Contributing $11,000 USD through a single shipment, constituting 0.2% of the total import value.

This concentration indicates a strategic choice by Biopharm Distribution SPA to establish strong partnerships with select suppliers, potentially ensuring favorable terms and consistent product quality. However, such dependency also introduces risks related to supply chain disruptions, pricing fluctuations, and geopolitical factors affecting the supplier's operations. The dominance of CIPLA LIMITED suggests a well-established and stable relationship, likely characterized by long-term contracts and mutual trust.

Biopharm Distribution SPA's supply chain resilience is closely tied to its sourcing strategy, which is heavily dependent on a limited number of suppliers. The company's primary supplier, CIPLA LIMITED, accounts for 99.8% of the total import value, indicating a deep reliance on this partnership. While this concentration may offer benefits such as negotiated pricing and assured product quality, it also exposes the company to potential risks. Disruptions in CIPLA LIMITED's operations, whether due to production issues, regulatory challenges, or geopolitical events, could significantly impact Biopharm Distribution SPA's ability to meet market demand. The company's limited engagement with other suppliers, such as J B CHEMICALS AND PHARMACEUTICALS LIMITED, suggests a lack of diversification in its supply chain, which could be a strategic consideration or a vulnerability.

Biopharm Distribution SPA's concentrated sourcing strategy positions the company to leverage strong relationships with key suppliers, potentially securing favorable terms and ensuring consistent product quality. This approach may also streamline logistics and inventory management. However, the heavy reliance on a single supplier introduces risks related to supply chain disruptions, pricing volatility, and geopolitical factors affecting the supplier's operations. For Indian exporters seeking to become alternative suppliers to Biopharm Distribution SPA, this presents an opportunity to diversify the company's supply base. By offering competitive pricing, high-quality products, and reliable delivery schedules, new suppliers can position themselves as viable alternatives, thereby reducing Biopharm Distribution SPA's dependency on a single source and enhancing the resilience of its supply chain.

In Algeria, the pharmaceutical industry is regulated by the Ministry of the Pharmaceutical Industry, which oversees the importation, distribution, and sale of pharmaceutical products. The regulatory framework governing pharmaceutical imports is outlined in Decree No. 24, issued on 1 October 2025. This decree establishes the requirements, procedures, and compliance obligations for licensing pharmaceutical import establishments in Algeria. It defines the content of the application file, processing and inspection procedures, and the rules governing substantial modifications, renewal, and withdrawal of authorizations granted. Authorized import establishments are required to align with the new requirements within 12 months of the decree's publication in the Official Journal.

To import pharmaceutical products into Algeria, establishments must obtain a license from the Ministry of the Pharmaceutical Industry. The application process involves submitting a comprehensive file that includes various documents, such as proof of compliance with Good Manufacturing Practices (GMP). Algeria recognizes GMP certifications from reputable international standards, including EU GMP, WHO GMP, and PIC/S. These certifications ensure that imported pharmaceutical products meet the required quality standards. Additionally, importers must possess wholesale distribution authorization, which is granted upon successful inspection and approval by the National Agency for Pharmaceutical Products.

Imported pharmaceutical products must undergo batch testing to ensure they meet the required quality standards. Stability requirements are enforced to guarantee that products remain effective and safe throughout their shelf life. Labeling must be in Arabic, the official language of Algeria, and should include all necessary information as stipulated by Algerian regulations. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market. These measures are part of Algeria's commitment to maintaining high standards in pharmaceutical product quality and safety.

In October 2025, Algeria's Ministry of the Pharmaceutical Industry issued Decree No. 24, which modernized the licensing requirements for pharmaceutical import establishments. This decree replaced the previous framework from December 2021, introducing updated procedures and compliance obligations. The new regulations aim to strengthen oversight of pharmaceutical import activities, enhance transparency, and ensure that imported products adhere to national and international manufacturing standards. Authorized import establishments are required to align with the new requirements within 12 months of the decree's publication in the Official Journal.

Biopharm Distribution SPA's product strategy focuses on importing pharmaceutical formulations that address a wide range of therapeutic areas, including respiratory, cardiovascular, and gastrointestinal treatments. This diverse product mix indicates a strategic approach aimed at meeting the comprehensive healthcare needs of the Algerian population. The company's emphasis on respiratory products, such as Budesonide and Formoterol, suggests a recognition of the prevalence of respiratory conditions in Algeria and a commitment to providing effective treatments. The substantial import value of these products underscores their significance in Biopharm Distribution SPA's portfolio and their importance in the Algerian pharmaceutical market.

Biopharm Distribution SPA's sourcing strategy is heavily concentrated on finished pharmaceutical formulations imported from India, with a particular focus on products from CIPLA LIMITED. This concentration indicates a strategic choice to establish strong partnerships with select suppliers, potentially ensuring favorable terms and consistent product quality. The company's limited engagement with other suppliers, such as J B CHEMICALS AND PHARMACEUTICALS LIMITED, suggests a preference for maintaining a streamlined supply chain with trusted partners. This approach may offer benefits such as negotiated pricing and assured product quality but also introduces risks related to supply chain disruptions and pricing fluctuations.

Based on its diverse product mix, Biopharm Distribution SPA serves multiple segments of the Algerian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's extensive import portfolio and distribution capabilities enable it to meet the needs of various healthcare providers and institutions across the country. By offering a wide range of pharmaceutical products, Biopharm Distribution SPA positions itself as a comprehensive supplier capable of addressing the diverse medical needs of the Algerian population.

There is a realistic opportunity for new Indian suppliers to enter Biopharm Distribution SPA's sourcing network. The